Frailty phenotypes and determinants of glucocorticoid-related adverse events in polymyalgia rheumatica at 12 months: a real-life single-center investigation

Key Points

• Glucocorticoid-related adverse events were prevalent among polymyalgia rheumatica patients at 12 months, highlighting significant risks.
• A total of 120 patients were evaluated, showing a marked association between frailty phenotypes and adverse outcomes over the year.
• The study utilized a single-center observational analysis to assess frailty and its effects on adverse events related to glucocorticoids.
• Understanding these determinants may lead to improved patient management strategies and reduce adverse effects in future treatments.